Blueg, We argued the same in the past, the baboon abstract and the title do not provide the benefits of the full article in terms of understanding. I post before the full article conclusions and it does not agree on with your view!
But, let's just for the sake of it say that We (meaning the blue and cacaito) agree that 1-the antibacterial properties are more important and 2-earlier use will provide an easy way to prove efficacy.
Then, We have a bigger problem, not an easier one:
If xoma's rbpi21 has minimal or none antiiflammatory activity then it is just another antibiotic, just more expensive to manufacture, and more strained to market, cause the abilities are less, the public will pay less.
The probable price of an effective first antishock product is on the range of $3,000 to $6,000 because of decrease use in resources in ICUs, plus the patients benefits, plus decrease disabilities, one could even assume a high price for the first in the class like $10,000. Well if rbpi21 is just an antibiotic for resistant organisms, or even for proven infections as an add on, one could reduce the price to 10% of a good antishock medication, and this will be a $300 to a high end $1000 per treatment, WAY expensive for a bug killer, even great antibiotics in the market are price as less than $500 per FULL course, and generics cut this to half of it, is rbpi21 so cheap to manufacture that will upset this devaluation?, other pedtides antibiotics are coming, so big competition in same class will come too.
Some of the most powerfull antibiotics like Metronidazole (generic of Flagyl)are less than $100 full course treatment!!, and the all flagships still useful like ampicillin and gentamicin are way below that!!!
If rbpi21 antiinflammatory effects are not important, then Why xoma was interested in trauma, ards prevention, post blood loss antiendotoxin block? (it failed, maybe you are right), Why the esoteric interest in Chlamydia-heart disease connection? pfizer Zythromax ($100 per treatment)and dirt cheap old erythromycin ($15 per treatment) do the same!!!, so what does rbpi21 at $1000 bucks will do better? or is it another concoction of xoma's feeble attempts?
Check this: "". The in vivo formation of tumor necrosis factor was significantly suppressed by the rBPI21 treatment regimen. Microcirculation and organ function were improved."" ...from the same abstract you constantly refer too, does that sound as just plain killing of bugs? No, and that is the hope of rbpi21 (and the reason I still followed this sad story, but not with my money).
Maybe, xoma has a trick and the drug is dirt cheap to manufacture, they already built the main expense, a $50M? facility if I remember well, please correct me if not.
If that is the case, well the antibiotic effect will be good enough to profit...
...But, Do you prefer another antibiotic at $100 vs an antibiotic-antishock-antiinflammatory $5,000? It just does not compute, is like the case of Gw prefering a restrain xoma's failure?
(his view, in my view xoma ceoperson behave like any of the so called rogue states, completely impervious with his full blown out of proportion and clearly misleading and malicious "clinical benefits" words, even way after fully knowing the months longs analysis and pre-pre-pre meetings-pre-BLA fda rejection, that is the essence of UNRESTRAIN!
Or do you prefer a real $5,000 ICU drug vs an eye drug that will take Allergan forever to figure out and compete with current $5 bucks eye drops? WOW.
It just does not compute, unless one is using the same computers that Gw say could not handle the complex analysis xoma was doing!!!
Of course Gw, the DR plantain power computers could not handle xoma's analysis, cause not even Kasparov defeating BigBlue could solve xoma's meningo trial, how could a computer reverse a FAILURE! |
